Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression

European Neuropsychopharmacology

Volumn 20, Issue 11, 2010, Pages 747-765

  Kasper, Siegfried ^a   Caraci, Filippo ^b   Forti, Bruno ^c   Drago, Filippo ^b   Aguglia, Eugenio ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF CATANIA   (Italy)

^c Engineering Division   (Italy)

Author keywords

Depression; Efficacy; Hypericum; Review; St. John's wort

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; MAPROTILINE; PAROXETINE; PLACEBO; SERTRALINE; STEI 300; UNCLASSIFIED DRUG; WS 5570; WS 5572; ZE 117;

CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR DEPRESSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STANDARD; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSION; DEPRESSIVE DISORDER; HUMANS; HYPERICUM; PHYTOTHERAPY; PLANT EXTRACTS; TREATMENT OUTCOME;

EID: 77957018511     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.07.005     Document Type: Review

References (115)

1. Aguglia E., Forti B. La depressione fra normalità e malattia. Aspetti clinici, sociali e terapeutici dei disturbi depressivi sottosoglia 2001, Il Pensiero Scientifico Editore, Roma.
2. Battaglia A., Dubini A., Mannheimer R., Pancheri P. Depression in the Italian community: epidemiology and socio-economic implications. Int. Clin. Psychopharmacol. 2004, 19:135-142.
3. Behnke K., Jensen G.S., Graubaum H.J., Gruenwald J. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv. Ther. 2002, 19:43-52.
4. Bergmann R., Nussner H., Demling J. Behandlung leichter bis mittelschwerer depressionen. Therapiewoche Neurol. Psychiatr. 1993, 7:235-240.
5. Bjerkenstedt L., Edman G.V., Alken R.G., Mannel M. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. Eur. Arch. Psychiatry Clin. Neurosci. 2005, 255:40-47.
6. Bove G.M. Acute neuropathy after exposure to sun in a patient treated with St John's wort. Lancet 1998, 352:1121-1122.
7. Brenner R., Azbel V., Madhusoodanan S., Pawlowska M. Comparison of an extract of Hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin. Ther. 2000, 22:411-419.
8. Brockmoller J., Reum T., Bauer S., Kerb R., Hübner W.D., Roots I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997, 30(Suppl 2):94-101.
9. Butterweck V. Mechanism of action of St John's wort in depression: what is known?. CNS Drugs 2003, 17:539-562.
10. Butterweck V., Schmidt M. St. John's wort: role of active compounds for its mechanism of action and efficacy. Wien. Med. Wochenschr. 2007, 157:356-361.
11. Cott J., Wisner K.L. St John's wort and depression. JAMA 2002, 288:448. author reply 448-449.
12. Demyttenaere K., Bruffaerts R., Albert A., Mesters P., Dewé W., Debruyckere K., Sangeleer M. Development of an antidepressant compliance questionnaire. Acta Psychiatr. Scand. 2004, 110:201-207.
13. Ernst E., Rand J.I., Barnes J., Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Eur. J. Clin. Pharmacol. 1998, 54:589-594.
14. Fahmi M., Huang C., Schweitzer I. A case of mania induced by Hypericum. World J. Biol. Psychiatry 2002, 3:58-59.
15. Fava G.A., Ruini C., Sonino N. Treatment of recurrent depression: a sequential psychotherapeutic and psychopharmacological approach. CNS Drugs 2003, 17:1109-1117.
16. Fava M., Alpert J., Nierenberg A.A., Mischoulon D., Otto M.W., Zajecka J., Murck H., Rosenbaum J.F. A double-blind, randomized trial of St. John's wort, fluoxetine, and placebo in major depressive disorder. J. Clin. Psychopharmacol. 2005, 25:441-447.
17. Franklin M., Hafizi S., Reed A., Hockney R., Murck H. Effect of sub-chronic treatment with Jarsin (extract of St John's wort, Hypericum perforatum) at two dose levels on evening salivary melatonin and cortisol concentrations in healthy male volunteers. Pharmacopsychiatry 2006, 39:13-15.
18. Gastpar M., Singer A., Zeller K. Efficacy and tolerability of Hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry 2005, 38:78-86.
19. Gastpar M., Singer A., Zeller K. Comparative efficacy and safety of a once-daily dosage of Hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry 2006, 39:66-75.
20. Geddes J.R., Carney S.M., Davies C., Furukawa T.A., Kupfer D.J., Frank E., Goodwin G.M. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003, 361:653-661.
21. Golsch S., Vocks E., Rakoski J., Brockow K., Ring J. Reversible increase in photosensitivity to UV-B caused by St. John's wort extract. Hautarzt 1997, 48:249-252.
22. Grundmann O., Lv Y., Kelber O., Butterweck V. Mechanism of St. John's wort extract (STW3-VI) during chronic restraint stress is mediated by the interrelationship of the immune, oxidative defense, and neuroendocrine system. Neuropharmacology 2010, 58:767-773.
23. Guzelcan Y., Scholte W.F., Assies J., Becker H.E. Mania during the use of a combination preparation with St. John's wort (Hypericum perforatum). Ned. Tijdschr. Geneeskd 2001, 145:1943-1945.
24. Hall S.D., Wang Z., Huang S.M., Hamman M.A., Vasavada N., Adigun A.Q., Hilligoss J.K., Miller M., Gorski J.C. The interaction between St John's wort and an oral contraceptive. Clin. Pharmacol. Ther. 2003, 74:525-535.
25. Hänsgen K.D., Vesper J. Antidepressive wirksamkeit eines hochdosierten Hypericum-extraktes. Münch. Med. Wochenschift 1996, 138:29-33.
26. Harrer G., Hubner W.D., Podzuweit H. Effectiveness and tolerance of the Hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. J. Geriatr. Psychiatry Neurol. 1994, 7(Suppl 1):S24-S28.
27. Harrer G., Schmidt U., Kuhn U., Biller A. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung 1999, 49:289-296.
28. Henderson L., Yue Q., Bergquist C., Gerden B., Arlett P. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br. J. Clin. Pharmacol. 2002, 54:349-356.
29. Hübner W.D., Lande S., Podzuweit H. Hypericum treatment of mild depressions with somatic symptoms. J Geriatr. Psychiatry Neurol. 1994, S1:S12-S14.
30. Hubner W.D., Arndt K.H. Johanniskraut-Einjahresstudie: Offene multizentrische Therapiestudie mit Johanniskraut-Extrakt LI 160 bei Patienten mit depressiven Erkrankungen. Zeitschr. f. Phytotherapie. 2000, 21:306-310.
31. Hypericum Depression Trial Study Group Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA 2002, 287:1807-1814.
32. Izzo A.A. Drug interactions with St. John's wort (Hypericum perforatum): a review of the clinical evidence. Int. J. Clin. Pharmacol. Ther. 2004, 42:139-148.
33. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., McQuay H.J. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control. Clin. Trials 1996, 17:1-12.
34. Kalb R., Trautmann-Sponsel R.D., Kieser M. Efficacy and tolerability of Hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial. Pharmacopsychiatry 2001, 34:96-103.
35. Kasper S., Dienel A. Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials. Psychopharmacology (Berl) 2002, 164:301-308.
36. Kasper S., Dienel A., Kieser M. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after successful acute treatment of mild to moderate depression-rationale and study design. Int. J. Meth. Psychiatr. Res. 2004, 13:176-183.
37. Kasper S., Anghelescu I.G., Szegedi A., Dienel A., Kieser M. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. BMC Med. 2006, 4:14.
38. Kasper S., Anghelescu I.G., Szegedi A., Dienel A., Kieser M. Placebo controlled continuation treatment with Hypericum extract WS 5570 after recovery from a mild or moderate depressive episode. Wien. Med. Wochenschr. 2007, 157:362-366.
39. Kasper S., Gastpar M., Müller W.E., Volz H.P., Dienel A., Kieser M., Möller H.J. Efficacy of St. John's wort extract WS 5570 in acute treatment of mild depression: a reanalysis of data from controlled clinical trials. Eur. Arch. Psychiatr. Clin. Neurosci. 2008, 258:59-63.
40. Kasper S., Volz H.P., Möller H.J., Dienel A., Kieser M. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression-a double-blind, randomized, placebo controlled long-term trial. Eur. Neuropsychopharmacol. 2008, 18:803-813.
41. Keller M.B., Hirschfeld R.M., Demyttenaere K., Baldwin D.S. Optimizing outcomes in depression: focus on antidepressant compliance. Int. Clin. Psychopharmacol. 2002, 17:265-271.
42. Kim H.L., Streltzer J., Goebert D. St. John's wort for depression: a meta-analysis of well-defined clinical trials. J. Nerv. Ment. Dis. 1999, 187:532-538.
43. Knuppel L., Linde K. Adverse effects of St. John's wort: a systematic review. J. Clin. Psychiatry 2004, 65:1470-1479.
44. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
45. Kumar A., Garg R., Prakash A.K. Effect of St. John's wort (Hypericum perforatum) treatment on restraint stress-induced behavioral and biochemical alteration in mice. BMC Complement. Altern. Med. 2010, 10:18.
46. Laakmann G., Schule C., Baghai T., Kieser M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998, 31(Suppl 1):54-59.
47. Lane-Brown M.M. Photosensitivity associated with herbal preparations of St John's wort (Hypericum perforatum). Med. J. Aust. 2000, 172:302.
48. Lecrubier Y., Clerc G., Didi R., Kieser M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am. J. Psychiatry 2002, 159:1361-1366.
49. Lehrl S., Woelk H. Ergebnisse von messungen der kognitiven leistungsfähigkeit bei patienten unter der therapie mit johanniskraut. Nervenheilkunde 1993, 12:281-284.
50. Lemmer W., von den Driesch V., Klieser E. Johanniskraut-spezialextrakt WS 5572 bei leichter bis mittelschwerer depression. Wirksamkeit und vertraglichkeit von neuroplant 300 filmbletten. Fortschr. Med. 1999, 117:143-154.
51. Linde K., Knuppel L. Large-scale observational studies of Hypericum extracts in patients with depressive disorders-a systematic review. Phytomedicine 2005, 12:148-157.
52. Linde K., Mulrow C.D. St John's wort for depression. Cochrane Database Syst. Rev. 2000, CD000448.
53. Linde K., Ramirez G., Mulrow C.D., Pauls A., Weidenhammer W., Melchart D. St John's wort for depression-an overview and meta-analysis of randomised clinical trials. BMJ 1996, 313:253-258.
54. Linde K., Melchart D., Mulrow C.D., Berner M. St John's wort and depression. JAMA 2002, 288:447-448. author reply 448-449.
55. Linde K., Berner M., Egger M., Mulrow C. St John's wort for depression: meta-analysis of randomised controlled trials. Br. J. Psychiatry 2005, 186:99-107.
56. Linde K., Mulrow C.D., Berner M., Egger M. St John's wort for depression (review). Cochrane Database Syst. Rev. 2005, 3:CD000448.
57. Linde K., Berner M.M., Kriston L. St John's wort for major depression. Cochrane Database Syst. Rev. 2008, CD000448.
58. Marsh W.L., Davies J.A. The involvement of sodium and calcium ions in the release of amino acid neurotransmitters from mouse cortical slices elicited by hyperforin. Life Sci. 2002, 71:2645-2655.
59. Mennini T., Gobbi M. The antidepressant mechanism of Hypericum perforatum. Life Sci. 2004, 75:1021-1027.
60. Mills E., Montori V., Wu P., Gallicano K., Clarke M., Guyatt G. Interaction of St John's wort with conventional drugs: systematic review of clinical trials. BMJ 2004, 329:27-30.
61. Moore L.B., Goodwin B., Jones S.A., Wisely G.B., Serabjit-Singh C.J., Willson T.M., Collins J.L., Kliewer S.A. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl Acad. Sci. U. S. A. 2000, 97:7500-7502.
62. Moreno R.A., Teng C.T., Almeida K.M., Tavares Junior H. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample. Rev. Bras. Psiquiatr. 2006, 28:29-32.
63. Moses E.L., Mallinger A.G. St. John's wort: three cases of possible mania induction. J. Clin. Psychopharmacol. 2000, 20:115-117.
64. Muller D., Pfeil T., von den Driesch V. Treating depression comorbid with anxiety-results of an open, practice-oriented study with St John's wort WS 5572 and valerian extract in high doses. Phytomedicine 2003, 10(Suppl 4):25-30.
65. Muller T., Mannel M., Murck H., Rahlfs V.W. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. Psychosom. Med. 2004, 66:538-547.
66. Mulsant B.H., Ganguli M. Epidemiology and diagnosis of depression in late life. J. Clin. Psychiatry 1999, 60(Suppl 20):9-15.
67. Nierenberg A.A., Burt T., Matthews J., Weiss A.P. Mania associated with St. John's wort. Biol. Psychiatry 1999, 46:1707-1708.
68. Nierenberg A.A., Quitkin F.M., Kremer C., Keller M.B., Thase M.E. Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse. Neuropsychopharmacology 2004, 229:1012-1018.
69. Olivier-Martin R. Psychological factors, compliance and resistance to antidepressant treatment. Encephale 1986, 12:197-203.
70. Olsen L.R., Mortensen E.L., Bech P. Prevalence of major depression and stress indicators in the Danish general population. Acta Psychiatr. Scand. 2004, 109:96-103.
71. Papakostas G.I., Crawford C.M., Scalia M.J., Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine. Neuropsychobiology 2007, 56:132-137.
72. Pfrunder A., Schiesser M., Gerber S., Haschke M., Bitzer J., Drewe J. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br. J. Clin. Pharmacol. 2003, 56:683-690.
73. Philipp M., Kohnen R., Hiller K.O. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicenter study of treatment for eight weeks. BMJ 1999, 319:1534-1538.
74. Rahimi R., Nikfar S., Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:118-127.
75. Reichling J., Hostanska K., Saller R. St. John' wort (Hypericum perforatum L.)-multicompound preparations versus single substances. Forsch. Komplementärmed. Klass. Naturheilkd 2003, 10(Suppl 1):28-32.
76. Röder C., Schaefer M., Leucht S. Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with St. John's wort. Fortschr. Neurol. Psychiatr. 2004, 72:330-343.
77. Rychlik R., Siedentop H., von den Driesch V., Kasper S. St. John's wort extract WS 5572 in minor to moderately severe depression. Effectiveness and tolerance of 600 and 1200mg active ingredient daily. Fortschr. Med. Orig. 2001, 119:119-128.
78. Schakau D., Hiller K.O., Schultz-Zehden W. Nutzen/risiko-profil von johanniskrautextrakt. Psychopharmakotherapie 1996, 3:116-122.
79. Schempp C.M., Ludtke R., Winghofer B., Simon J. Effect of topical application of Hypericum perforatum extract (St. John's wort) on skin sensitivity to solar simulated radiation. Photodermatol. Photoimmunol. Photomed. 2000, 16:125-128.
80. Schmidt U., Sommer H. St. John's wort extract in the ambulatory therapy of depression. Attention and reaction ability are preserved. Fortschr. Med. 1993, 111:339-342.
81. Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int. Clin. Psychopharmacol. 2000, 15:61-68.
82. Schrader E., Meier B., Brattstrom A. Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicenter study. Hum. Psychopharmacol. 1998, 13:163-169.
83. Schule C., Baghai T., Ferrera A., Laakmann G. Neuroendocrine effects of Hypericum extract WS 5570 in 12 healthy male volunteers. Pharmacopsychiatry 2001, 34:S127-S133.
84. Schulz V. Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomedicine 2001, 8:152-160.
85. Schulz V. Safety of St. John's wort extract compared to synthetic antidepressants. Phytomedicine 2006, 13:199-204.
86. Shaper & Brummer. Esbericum capsules. Release date: 2005. Accessed on: 28 February, 2005. Available from: http://www.schaper-bruemmer.de/SUB_ICM_EN.NSF/(html)/Frameset_load?OpenDocument&003Products_004Esbericum_002EsbericumKapseln_000EsbericumCapsules?OpenDocument&AllgNav_dsp?OpenForm&Kat0_root.
87. Shelton R.C., Keller M.B., Gelenberg A., Dunner D.L., Hirschfeld R., Thase M.E., Russell J., Lydiard R.B., Crits-Cristoph P., Gallop R., Todd L., Hellerstein D., Goodnick P., Keitner G., Stahl S.M., Halbreich U. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 2001, 285:1978-1986.
88. Simbrey K., Winterhoff H., Butterweck V. Extracts of St. John's wort and various constituents affect beta-adrenergic binding in rat frontal cortex. Life Sci. 2004, 74:1027-1038.
89. +. J. Pharmacol. Exp. Ther. 1999, 290:1363-1368.
90. Sommer H., Harrer G. Placebo-controlled double-blind study examining the effectiveness of an Hypericum preparation in 105 mildly depressed patients. J. Geriatr. Psychiatry Neurol. 1994, 7(Suppl 1):S9-S11.
91. Spielmans G.I. St John's wort and depression. JAMA 2002, 288:446-447. author reply 448-449.
92. Stassen H.H., Kuny S., Hell D. The speech analysis approach to determining onset of improvement under antidepressants. Eur. Neuropsychopharmacol. 1998, 8:303-310.
93. Stewart J.W., Quitkin F.M., McGrath P.J., Amsterdam J., Fava M., Fawcett J., Reimherr F., Rosenbaum J., Beasley C., Roback P. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1year of treatment with fluoxetine or placebo. Arch. Gen. Psychiatry 1998, 55:334-343.
94. Szegedi A., Muller M.J., Anghelescu I., Klawe C., Kohnen R., Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J. Clin. Psychiatry 2003, 64:413-420.
95. Szegedi A., Kohnen R., Dienel A., Kieser M. Acute treatment of moderate to severe depression with Hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ 2005, 330:503.
96. Tai-Seale M., Croghan T.W., Obenchain R. Determinants of antidepressant treatment compliance: implications for policy. Med. Care Res. Rev. 2000, 57:491-512.
97. Taylor L.H., Kobak K.A. An open-label trial of St. John's wort (Hypericum perforatum) in obsessive-compulsive disorder. J. Clin. Psychiatry 2000, 61:575-578.
98. van Gurp G., Meterissian G.B., Haiek L.N., McCusker J., Bellavance F. St John's wort or sertraline? Randomized controlled trial in primary care. Can. Fam. Physician 2002, 48:905-912.
99. Volp A. St John's wort and depression. JAMA 2002, 288:447. author reply 448-449.
100. Volz H.P., Laux P. Potential treatment for subthreshold and mild depression: a comparison of St. John's wort extracts and fluoxetine. Compr. Psychiatry 2000, 41:133-137.
101. Volz H.P., Murck H., Kasper S., Moller H.J. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology (Berl) 2002, 164:294-300.
102. Vorbach E.U., Hubner W.D., Arnoldt K.H. Effectiveness and tolerance of the Hypericum extract LI 160 in comparison with imipramine: randomized double-blind study with 135 outpatients. J. Geriatr. Psychiatry Neurol. 1994, 7(Suppl 1):S19-S23.
103. Wagner H., Bladt S. Pharmaceutical quality of Hypericum extracts. J. Geriatr. Psychiatry Neurol. 1994, 7(Suppl 1):S65-S68.
104. Westerhoff K., Kaunzinger A., Wurglics M., Dressman J., Schubert-Zsilavecz M. Biorelevant dissolution testing of St John's wort products. J. Pharm. Pharmacol. 2002, 54:1615-1621.
105. Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients-a controlled 6-week clinical trial. Pharmacopsychiatry 1997, 30(Suppl 2):77-80.
106. Wheatley D. St John's wort and depression. JAMA 2002, 288:446. author reply 448-449.
107. Whiskey E., Werneke U., Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. Int. Clin. Psychopharmacol. 2001, 16:239-252.
108. Whitten D.L., Myers S.P., Hawrelak J.A., Wohlmuth H. The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. Br. J. Clin. Pharmacol. 2006, 62:512-526.
109. Wilhelm K., Mitchell P., Slade T., Brownhill S., Andrews G. Prevalence and correlates of DSM-IV major depression in an Australian national survey. J. Affect. Disord. 2003, 75:155-162.
110. Witte B., Harrer G., Kaptan T., Podzuweit H., Schmidt U. Treatment of depressive symptoms with a high concentration Hypericum preparation. A multicenter placebo-controlled double-blind study. Fortschr. Med. 1995, 113:404-408.
111. Woelk H. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. BMJ 2000, 321:536-539.
112. Woelk H., Burkard G., Grunwald J. Benefits and risks of the Hypericum extract LI 160: drug monitoring study with 3250 patients. J. Geriatr. Psychiatry Neurol. 1994, 7(Suppl 1):S34-S38.
113. Yoshitake T., Iizuka R., Yoshitake S., Weikop P., Müller W.E., Ogren S.O., Kehr J. Hypericum perforatum L (St John's wort) preferentially increases extracellular dopamine levels in the rat prefrontal cortex. Br. J. Pharmacol. 2004, 142:414-418.
114. Zeller K. A convincing safety profile of St. John's wort extract (Laif 600) shown in a large post marketing surveillance. Phytomedicine 2000, 7:107.
115. Zhou S.F., Lai X. An update on clinical drug interactions with the herbal antidepressant St. John's wort. Curr. Drug Metab. 2008, 5:394-409.